COMMUNIQUÉS West-GlobeNewswire

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center
15/07/2026
- The ADMIRE study, by treating immunocompromised patients, builds on the momentum of Alpha Tau's ReSTART pivotal trial for recurrent cSCC, which recently completed patient enrollment, under which the Banner MD Anderson [...]
NDT Pharmaceuticals, Inc.’s Wholly Owned Subsidiary Good Salt Life, Inc. Reports Strong Online Retail Growth in First Half of 2026
15/07/2026
ATHENS, Ga., July 15, 2026 (GLOBE NEWSWIRE) -- NDT Pharmaceuticals, Inc. (OTC: NDTP) announces that its wholly owned subsidiary Good Salt Life, Inc. (“GSL” or the “Company”) achieved significant growth across its online [...]
Cannara Reports Record Q3 Revenues and Continued Profitability Accompanied By Expanding National Distribution and Accelerated Capacity Expansion
15/07/2026
Delivered strong Q3 financial results: Generated $31.8 million in total net revenues, $13.4 million in gross profit before fair value adjustments, or 42% of revenues, $8.5 million in adjusted EBITDA 1 , and $5.7 million [...]
BioAdaptives® Inc. Announces XcellaraHeart™, a Cardiovascular Wellness Formula Built on Xcellara’s Human-Clinical Data Demonstrating a 268.8% Increase in Circulating Stem/Progenitor-Type Cells
15/07/2026
The formula combines the Xcellara™ mobilization base with Tanshinone IIA, a Danshen-derived compound studied for its effects on the SDF-1α/CXCR4 signaling pathways involved in cellular trafficking and cardiovascular [...]
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
15/07/2026
Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvements in multiple PROs for 5.0 mg/kg efzofitimod compared to placebo. Company submitted protocol to FDA in June 2026 for [...]
iTonic Holdings Ltd Issues an Update on its Effort to Develop AI-Powered Cloud Healthcare Platform Designed to Support Nuclear Medicine Treatment Planning and with Potential Future Expansion into Digital Care Delivery
15/07/2026
New cloud-based platform is being developed to integrate artificial intelligence, automated quality control and healthcare data connectivity to support next-generation precision medicine workflows. Beijing, China, July [...]
Slate Medicines Strengthens Board of Directors with Appointment of Mark W. Hahn
15/07/2026
RALEIGH, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- Slate Medicines (Slate), a privately-held biotech company advancing next-generation therapeutics for migraine and other headache disorders, today announced the [...]
New FDA-Cleared Single-Step Immunoblot IGeneX Tests Improve Early Detection of Lyme Disease, Study Finds
15/07/2026
Study published in Microbiology Spectrum shows single-step tests outperform conventional two-tier testing in early-stage Lyme disease MILPITAS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- IGeneX, Inc ., a specialty [...]
Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026
15/07/2026
DUBLIN, Ireland and BRIDGEWATER, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will [...]
Cardiff Oncology Announces $10 Million Registered Direct Offering
15/07/2026
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (the “Company”), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced [...]
Mixie Technologies, Inc. (OTC: MIXE) Completes Corporate Rebranding and Trading Symbol Change
15/07/2026
Mixie Technologies focuses on acquiring companies and intellectual property built on unique, application-focused technology designed to deliver an advantage to customers, then scales them with AI-driven engineering [...]
Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
15/07/2026
Appointments strengthen financial and scientific leadership to help advance multiple ultra-long-acting incretin and non-incretin therapies toward the clinic EMERYVILLE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Prolynx [...]
Persephoni Backs SelSym Biotech to Bring Blood-Type-Agnostic Bleeding Control to the Point of Injury
15/07/2026
SelSym Biotech joins Persephoni to advance the first shelf-stable, blood-type agnostic hemostatic therapy designed for use at the point of injury, where no such option exists today RESEARCH TRIANGLE PARK, N.C., July 15 [...]
Biogen Appoints Michael J. Parini as Chief Legal Officer
15/07/2026
CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini will serve as a member of [...]
BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026
15/07/2026
MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, [...]
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
15/07/2026
The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases. Rectify is developing oral [...]
Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation
15/07/2026
Up to 84% of GLP-1 induced weight loss retained with Revita® versus 46% with sham at one year in patients receiving complete duodenal ablations Next anticipated Revita® milestones are topline six-month randomized data [...]
Nxera Pharma Webinar for Financial Results Presentation - 2Q2026
15/07/2026
Tokyo, Japan and Cambridge and London, UK, 15 July 2026 – Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for 2Q 2026 on Friday, 7 August 2026. The Company [...]
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
15/07/2026
Company Announcement Net sales of DARZALEX ® in the second quarter of 2026 totaled USD 4,207 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, [...]

Pages